The mean follow-up duration was 17

The mean follow-up duration was 17.8?a few months. significantly higher occurrence of main (9.0 vs. 4.1 events/100 patient-years; occurrence rate proportion [IRR] 2.18, 95?% self-confidence period [CI] 1.32C3.68) and clinically relevant nonmajor bleeding (14.8 vs. 8.0 events/100 patient-years; IRR 1.85, 95?% CI 1.27C2.71) than sufferers without polypharmacy. After modification, polypharmacy Continue Reading